20 articles
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
Study tested whether pimavanserin could prevent return of hallucinations and delusions in dementia patients who initially responded to treatment.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Swiss researchers tested whether paroxetine reduces LSD response by downregulating serotonin receptors in healthy adults.
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
A Phase II trial tests whether blocking herpes virus activity can protect against Alzheimer's disease in early cognitive decline.
Combining Mediterranean-DASH diet with nature therapy targets hypertension and cognitive decline in older adults.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
